COMMUNIQUÉS West-GlobeNewswire

BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis
19/08/2025
U.S. FDA has placed a clinical hold on the Phase 2b study as it reviews data submitted by BiomX on third-party nebulizer used to deliver BX004; no concerns were raised in the clinical hold notification regarding the [...]
Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call
19/08/2025
Call Scheduled for today, Tuesday, August 19, 2025, at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and [...]
Walking Alone at Night is the Greatest Safety Fear of Women Nationwide -- Almost Half Say Safety Concerns Limit Daily Activities LogicMark Poll Reveals
19/08/2025
More women turn to technology solutions, with 71% looking to discreet devices for safety LOUISVILLE, Ky., Aug. 19, 2025 (GLOBE NEWSWIRE) -- A comprehensive new national survey commissioned by LogicMark, Inc. (OTC: LGMK [...]
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ
19/08/2025
MELBOURNE, Australia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from [...]
Intelligent Bio Solutions Achieves Record Monthly Sales of 12,500+ Units of Higher-Margin Cartridges in July
19/08/2025
Company reports all-time-high monthly cartridge sales for July with 60% year-on-year growth NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical [...]
Cannabix Technologies delivers Marijuana Breath Test Hardware to Omega Laboratories Inc.
19/08/2025
VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) reports that it has delivered multiple Cannabix [...]
Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights
19/08/2025
Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301 Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026 KANSAS CITY, Kan., Aug. 19, 2025 (GLOBE NEWSWIRE [...]
Tria Federal Promotes Murali Mallina to Chief Technology Officer
19/08/2025
ARLINGTON, Va., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tria Federal (Tria) has promoted Murali Mallina to be the company’s new Chief Technology Officer (CTO). As CTO, Mallina will lead Tria Labs, Tria’s technology innovation [...]
60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
19/08/2025
90-day trial measuring change in general fatigue in chronic babesiosis patients Enrollment expected to commence Q4 2025 and to be completed by Q2 2026 Site has clinical expertise in infectious disease trials and access [...]
Best Kratom Brand 2025: OnPattison Reviews Happy Go Leafy for Premium Kratom Products and Strains
19/08/2025
On Pattison names Happy Go Leafy the Best Kratom Brand 2025, highlighting third-party testing, COA transparency, and diverse product offerings. Miami, Florida, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Happy Go Leafy has been [...]
Scientists Discuss the Recent CancerVax Breakthrough
19/08/2025
The Company's scientific team describes how they successfully disguised cancer cells and tricked immune cells into attacking them and reveals the next phase of their development plan Lehi, Aug. 19, 2025 (GLOBE NEWSWIRE [...]
ITM to Present New Subgroup Analysis Data from the COMPETE Trial at ESMO 2025 and Host an Educational Event for Healthcare Professionals
19/08/2025
Garching / Munich, Germany, August 19, 2025 – ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, today announced that further data on efficacy, safety and subgroup analysis from [...]
Idorsia publishes end results of repurchase offer for its 2025 and 2028 convertible bonds
19/08/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – August 19, 2025 Idorsia Ltd (SIX: IDIA) announces the end results of the repurchase offer for its outstanding CHF 204 * million convertible bonds [...]
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
19/08/2025
August 19, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it [...]
Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries
19/08/2025
Pratteln, Switzerland , 19 August , 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab [...]
Basilea on track with strong 2025 half-year results
19/08/2025
Cresemba ® and Zevtera ® -related revenues rise by 24% to CHF 90.5 million Total revenue grows significantly by 36% to CHF 104.0 million Operating profit surges by 160% to CHF 24.0 million Operating cash flow increases [...]
Coloplast A/S - Announcement no. 05/2025 - Coloplast announces changes to Executive Leadership Team
19/08/2025
Coloplast announces changes to Executive Leadership Team The Coloplast Board of Directors are making changes to the Executive Leadership Team (ELT) to support the successful execution of the new Coloplast Group strategy [...]
Coloplast A/S - Interim Financial Report, 9M 2024/25
19/08/2025
2024/25 Interim financial results, 9M 2024/25 1 October 2024 - 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin 1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from [...]
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
19/08/2025
SINGAPORE, Aug. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary [...]

Pages